Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease.
作者信息
Kow Chia Siang, Hasan Syed Shahzad
机构信息
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
Department of Pharmacy, University of Huddersfield, Huddersfield, UK.
出版信息
Rheumatol Int. 2020 Dec;40(12):2117-2118. doi: 10.1007/s00296-020-04715-0. Epub 2020 Oct 12.
Abstract
摘要
相似文献
1
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease.利妥昔单抗的使用与患有系统性风湿疾病的COVID-19患者不良临床结局的风险
Rheumatol Int. 2020 Dec;40(12):2117-2118. doi: 10.1007/s00296-020-04715-0. Epub 2020 Oct 12.
2
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.由于 SARS-CoV-2 感染，接受利妥昔单抗治疗的风湿性疾病患者出现严重疾病和死亡的比率较高：一项描述性研究。
Rheumatol Int. 2020 Dec;40(12):2015-2021. doi: 10.1007/s00296-020-04699-x. Epub 2020 Sep 18.
3
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.如何在 COVID-19 时代处理自身免疫性风湿和炎症性肠病患者：专家意见。
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
4
Rheumatology in a time of Coronavirus: lessons from our early experiences.新冠疫情下的风湿病学：我们早期经验的教训
QJM. 2020 Oct 1;113(10):715-716. doi: 10.1093/qjmed/hcaa163.
5
Who Needs a Corona?谁需要新冠病毒？
Arthritis Rheumatol. 2020 Jun;72(6):874-876. doi: 10.1002/art.41260. Epub 2020 Apr 20.
6
Management of pediatric rheumatic patients in Kazakhstan during the coronavirus disease 2019 (COVID-19) pandemic.2019年冠状病毒病（COVID-19）大流行期间哈萨克斯坦儿科风湿病患者的管理
Rheumatol Int. 2020 Aug;40(8):1351-1352. doi: 10.1007/s00296-020-04613-5. Epub 2020 Jun 8.
7
Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR.2019冠状病毒病大流行期间风湿病患者的护理：亚太风湿病学联盟的立场声明
Int J Rheum Dis. 2020 Jun;23(6):717-722. doi: 10.1111/1756-185X.13863. Epub 2020 May 27.
8
[Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic].[德国风湿病学会关于SARS-CoV-2/新冠疫情期间风湿病患者护理的当前指南]
Z Rheumatol. 2020 May;79(4):385-388. doi: 10.1007/s00393-020-00799-y.
9
No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic.在SARS-CoV-2大流行期间，接受IL-6R抑制剂治疗的意大利风湿病患者出现呼吸道症状的风险并不更高。
Rheumatology (Oxford). 2020 Sep 1;59(9):2644-2646. doi: 10.1093/rheumatology/keaa388.
10
Self-care recommendations for patients with rheumatic diseases during the COVID-19 pandemic.2019冠状病毒病大流行期间风湿病患者的自我护理建议。
Rheumatol Int. 2020 Aug;40(8):1347-1349. doi: 10.1007/s00296-020-04614-4. Epub 2020 Jun 2.
引用本文的文献
1
Plasmapheresis for Facilitating Readministration of Rituximab After Paradoxical Exacerbation in Pemphigus Vulgaris: A Case Report.血浆置换促进寻常型天疱疮矛盾性加重后利妥昔单抗的再次给药：一例报告
Clin Case Rep. 2025 Apr 6;13(4):e70375. doi: 10.1002/ccr3.70375. eCollection 2025 Apr.
2
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study.替沙格韦单抗-西加韦单抗预防接受抗CD20单克隆抗体治疗的血液病患者发生重症新型冠状病毒肺炎：一项国际多中心研究
Infect Dis Ther. 2025 Jan;14(1):167-180. doi: 10.1007/s40121-024-01089-9. Epub 2024 Dec 9.
3
Harnessing immunity: Immunomodulatory therapies in COVID-19.利用免疫：COVID-19中的免疫调节疗法。
World J Virol. 2024 Jun 25;13(2):92521. doi: 10.5501/wjv.v13.i2.92521.
4
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.一项国际多中心研究比较了奥密克戎变异株在接受奥滨尤妥珠单抗与利妥昔单抗治疗的血液系统恶性肿瘤患者中的结局。
Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997.
5
Systematic review and meta-analysis of anti-CD20 treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes.系统评价和荟萃分析抗 CD20 治疗 COVID-19 患者：严重疾病和死亡率结局评估。
Inflammopharmacology. 2023 Dec;31(6):3339-3355. doi: 10.1007/s10787-023-01349-z. Epub 2023 Oct 7.
6
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.CovAID：炎症性风湿病或自身免疫性疾病患者中与重症COVID-19相关因素的识别
Front Med (Lausanne). 2023 Mar 22;10:1152587. doi: 10.3389/fmed.2023.1152587. eCollection 2023.
7
Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.在2019冠状病毒病大流行期间使用免疫抑制疗法治疗天疱疮的考量，重点关注利妥昔单抗：来自澳大利亚单一中心经验的病例报告
Front Med (Lausanne). 2023 Mar 14;10:1149742. doi: 10.3389/fmed.2023.1149742. eCollection 2023.
8
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.新冠疫情期间的自身免疫性大疱性疾病：2022年利妥昔单抗与疫苗最新进展
Front Med (Lausanne). 2023 Jan 19;10:1112823. doi: 10.3389/fmed.2023.1112823. eCollection 2023.
9
Prolonged -CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy.两名接受抗 CD20 治疗的患者中出现了具有共同特征的持续性 -CoV-2 感染。
In Vivo. 2023 Jan-Feb;37(1):461-467. doi: 10.21873/invivo.13100.
10
Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak.风湿性肌肉骨骼疾病中生物类 DMARDs 的安全性：COVID-19 爆发的前两个波次中的基于人群研究。
Viruses. 2022 Jul 1;14(7):1462. doi: 10.3390/v14071462.
本文引用的文献
1
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.由于 SARS-CoV-2 感染，接受利妥昔单抗治疗的风湿性疾病患者出现严重疾病和死亡的比率较高：一项描述性研究。
Rheumatol Int. 2020 Dec;40(12):2015-2021. doi: 10.1007/s00296-020-04699-x. Epub 2020 Sep 18.
2
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.西班牙 4035 例连续住院 COVID-19 患者的死亡特征和预测因素。
Clin Microbiol Infect. 2020 Nov;26(11):1525-1536. doi: 10.1016/j.cmi.2020.07.024. Epub 2020 Aug 4.
3
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.生物制剂增加了感染 SARS-CoV-2 和住院的风险，但不会增加 ICU 收治和死亡的风险：在红色区域宣布期间来自大型队列的真实数据。
Dermatol Ther. 2020 Sep;33(5):e13475. doi: 10.1111/dth.13475. Epub 2020 May 19.
4
Virological assessment of hospitalized patients with COVID-2019.住院 COVID-19 患者的病毒学评估。
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
5
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.新型冠状病毒病 2019 患者的 SARS-CoV-2 抗体反应。
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. doi: 10.1093/cid/ciaa344.
6
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.SARS-CoV-2 感染后口咽后唾液样本和血清抗体反应中的病毒载量时间特征：一项观察性队列研究。
Lancet Infect Dis. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1. Epub 2020 Mar 23.
7
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.生物性改善病情抗风湿药治疗对类风湿关节炎患者严重感染后发生脓毒症或死亡风险的影响。
Ann Rheum Dis. 2016 Sep;75(9):1667-73. doi: 10.1136/annrheumdis-2015-207838. Epub 2015 Nov 13.
8
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.类风湿关节炎临床试验中接受利妥昔单抗治疗的患者的长期安全性。
J Rheumatol. 2010 Mar;37(3):558-67. doi: 10.3899/jrheum.090856. Epub 2010 Jan 28.
Zotero 插件